CpG 684: an effective adjuvant for the inactivated COVID-19 vaccine in mice.

Authors:
Liu J; Cang T; Jiang C; Li K; Liu S and 5 more

Journal:
Future Virol

Publication Year: 2023

DOI:
10.2217/fvl-2022-0172

PMCID:
PMC10241461

PMID:
38051998

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Future Virol

Abbreviation: Future Virol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Virology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Antiviral attributes of bee venom as a possible therapeutic approach against SARS-CoV-2 infection.
Goswami S; Chowdhury JP. (2023) - Transparency Score: 2/6
DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes.
Nag S; Mandal S; Mukherjee O and 2 more (2023) - Transparency Score: 3/6
Natural killer cells in COVID-19: from infection, to vaccination and therapy.
Zafarani A; Razizadeh MH; Pashangzadeh S and 3 more (2023) - Transparency Score: 2/6
Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient …
Horga A; Saenz R; Yilmaz G and 13 more (2023) - Transparency Score: 4/6
Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID…
Horga A; Kuritzkes DR; Kowalczyk JJ and 5 more (2023) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest disclosure: The authors declare that there are no conflicts of interest present."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025